BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Corcept (CORT)CorceptEarnings

Revenue of $340.5 million, a 64 percent increase over the same period in 2025 Korlym ® and authorized generic product revenue of $249.1 million Lifyorli ® product revenue of $91.4 million Reiterated 2026 revenue guidance of $1.1 – $1.2 billion Net income of $126.8 million, compared to $19.7

Related news

CORTCorcept2026-10-27 20:05 EST

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-07-29 20:05 EST

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-10-28 20:05 EST

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

NBIXNeurocrine Biosciences2026-11-02 21:49 EST

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

AMPHAmphastar Pharmaceuticals, Inc.2021-03-15 20:05 EST

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

AMPHAmphastar Pharmaceuticals, Inc.2020-10-29 20:05 EST

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020

View all latest news

Corcept

Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...

Recent company news

CORTCorcept2026-11-03 21:05 EST

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-10-27 20:05 EST

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-10-26 12:00 EST

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-10-20 20:00 EST

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

CORTCorcept2026-09-23 12:00 EST

Corcept Announces Planned Leadership Transition

Stock data

Close
71.63 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States